ng28ÄϹ¬ºÍ²³½¡Ðû²¼
£¬Å·ÖÞÒ©Æ·ÖÎÀí¾Ö£¨CHMP£©ÒѾö¶¨Î¬³ÖÆäÔÚ2024Äê11ÔÂͨ¹ýµÄ¹ØÓÚ¿¹A¦Âµ¥¿Ë¡¿¹ÌåÂØ¿¨Ä¹£¨ÉÌÆ·Ãû£ºÀÖÒâ±£?/Leqembi?£©µÄÅú×¼½¨Òé¹
¡£»ùÓÚCHMPµÄÉó²é½á¹û
£¬Å·ÖÞίԱ»á£¨EC£©½«ÖØÐÂÆô¶¯¶ÔÂØ¿¨Ä¹ÉÏÊÐÐí¿ÉµÄ¾ö²ßÁ÷³Ì
¡£

2025Äê1ÔÂ
£¬Å·ÖÞίԱ»á£¨EC£©ÔÚÆä¾ö²ßÁ÷³ÌÖÐÒªÇóÅ·ÖÞÒ©Æ·ÖÎÀí¾Ö£¨CHMP£©Æ¾¾Ý2024Äê11ÔÂÅú×¼½¨ÒéͨʺóËù»ñÈ¡µÄÂØ¿¨Ä¹Äþ¾²ÐÔÐÅÏ¢
£¬ÖØÐÂÈ·ÈÏÊÇ·ñÐèÒª¸üÐÂÅú×¼½¨Òé
£¬²¢È·ÈÏÅú×¼½¨ÒéÖйØÓÚΣº¦×îС»¯²½·¥µÄÃèÊöÊÇ·ñ×ã¹»Ã÷È·
¡£¾­Éó²é
£¬CHMPµÃ³ö½áÂÛ
£¬ÈÏΪÎÞÐè¸üжÔÂØ¿¨Ä¹µÄÅú×¼½¨Òé
¡£

Å·ÖÞ°¢¶û´Äº£Ä¬²
¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­£¨MCI£©ºÍ°¢¶û´Äº£Ä¬ÐͳմôµÄ»¼ÕßÈËÊý»®·ÖÔ¤¼ÆΪ1520ÍòÈ˺Í690ÍòÈ˲
¡£°¢¶û´Äº£Ä¬²
¡£¨AD£©»áËæʱ¼äÖ𽥶ñ»¯
£¬²¡ÇéµÄ¼ÓÖز»µ«¶ÔAD»¼Õß×Ô¼º¼°Æ令ÀíÈËÔ±Ôì³É¾Þ´óµ£¸º
£¬Ò²¶ÔÕû¸öÉç»á±¬·¢ÖØ´óÓ°Ïì
¡£Ä¿Ç°ÆÈÇÐÐèÒªÄܹ»´ÓÔçÆڽ׶ÎÑÓ»ºAD½øÕ¹µÄÐÂÖÎÁÆÑ¡Ôñ
¡£

Èç¹ûÂØ¿¨Ä¹µÄÉÏÊÐÐí¿ÉÉêÇë»ñµÃECÅú×¼
£¬¸ÃÅú×¼½«ÊÊÓÃÓÚËùÓÐ27¸öÅ·Ã˳ÉÔ±¹úÒÔ¼°±ùµº¡¢ÁÐÖ§¶ØÊ¿µÇºÍŲÍþ
¡£ng28ÄϹ¬ºÍ²³½¡½«¼ÌÐøÈ«Á¦ÒÔ¸°
£¬¾¡¿ì½«ÂØ¿¨Ä¹ÌṩӦŷÖÞµÄÔçÆÚAD»¼Õß
¡£

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉng28ÄϹ¬Ö÷µ¼
£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã
¡£ÆäÖÐ
£¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ
¡£

 

²Î¿¼×ÊÁÏ£º

1. Committee for Medicinal Products for Human Use. 2024. Leqembi (Lecanemab). Overview. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi#overview Last accessed:January 2025
2. Gustavsson, A., et al. Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimer¡¯s & Dementia. 2023;19:658-670. https://alzjournals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12694.

 

±àºÅ£ºECN-2025-0019